WO2002096860A1 - Process for preparing sertraline intermediates - Google Patents

Process for preparing sertraline intermediates Download PDF

Info

Publication number
WO2002096860A1
WO2002096860A1 PCT/FI2002/000466 FI0200466W WO02096860A1 WO 2002096860 A1 WO2002096860 A1 WO 2002096860A1 FI 0200466 W FI0200466 W FI 0200466W WO 02096860 A1 WO02096860 A1 WO 02096860A1
Authority
WO
WIPO (PCT)
Prior art keywords
dichlorophenyl
dihydro
sertraline
cis
formula
Prior art date
Application number
PCT/FI2002/000466
Other languages
French (fr)
Inventor
Ilpo Laitinen
Pekka PIETIKÄINEN
Original Assignee
Orion Corporation Fermion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20011146A external-priority patent/FI20011146A0/en
Application filed by Orion Corporation Fermion filed Critical Orion Corporation Fermion
Priority to CA002448300A priority Critical patent/CA2448300A1/en
Priority to EP02727626A priority patent/EP1397342A1/en
Publication of WO2002096860A1 publication Critical patent/WO2002096860A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/02—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of compounds containing imino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • C07C209/86—Separation
    • C07C209/88—Separation of optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • the present invention relates to a novel method for the production of sertraline.
  • the present invention also relates to a novel process for the preparation of a pharmaceutical intermediate, N-[4-(3,4-dichlorophenyl)-3,4-dihydro-l(2H)- naphtalenylidene]methanamine.
  • Sertraline is marketed in the form of its hydrochloride for the treatment of depression, obsessive-compulsive disorder and panic disorder.
  • reaction is an equilibrium reaction, where the equilibrium has to be shifted. This can be done e.g. by using titanium tetrachloride to remove water from the reaction mixture. Titanium tetrachloride, however, is extremely reactive with water and side products formed are hazardous, and therefore other dehydrating agents have been considered.
  • (+) enantiomer of sertraline is prepared by either of the processes described above using (+) enantiomer of 4-(3,4- dichlorophenyl)-3,4-dihydro-l(2H)-naphtalenone as a starting material, so that no resolution of the final product is needed.
  • Still another route to to N-4-[3,4-dichlorophenyl)-3,4-dihydro-l(2H)- naphtalenylidene]methanamine is described in the patent application WO 99/36394.
  • Sertraline hydrochloride is produced by further hydrogenating the N-4-[3,4- dichlorophenyl)-3,4-dihydro-l(2H)-naphtalenylidene]methanamine resulted from processes above and resolving the racemic mixture and finally crystallizing sertraline hydrochloride.
  • the reaction can be performed in atmospheric pressure and ambient temperature. Also the amount of the solvent needed is low, impurities are not formed and the yield is good. Water removal agents like titanium tetrachloride or molecular sieves are not needed.
  • Another aspect of this invention relates to the process wherein the imine product formed in the process of the invention is hydrogenated to form sertraline which is further resolved by e.g. mandelic acid and finally crystallized as (lS-cis)-4- (3,4-dichlorophenyl)-l,2,3,4-tetrahydro-N-methyl-l-naphthalenamine hydrochloride or some other pharmaceutically suitable salt.
  • Still another aspect of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising ( 1 S-cis)-4-(3,4-dichlorophenyl)- 1 ,2,3 ,4-tetrahydro-N-methyl- 1 - naphthalenamine or its hydrochloride or some other pharmaceutically suitable salt prepared by the process of the invention.
  • the present invention provides a process for producing N-[4-(3,4-dichlorophenyl)-3,4-dihydro-l(2H)-naphthalenylidene]methanamine, by reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)-naphthalenone with monomethylamine in a solvent selected from the a group consisting of amide solvents of general formula IV:
  • Rl and R3 are independently hydrogen or C 1-6 alkyl, which can be substituted, and R2 is hydrogen.
  • the present invention provides a process wherein the N-[4-(3,4-dichlorophenyl)-3,4-dihydro- 1 (2H)-naphthalenylidene]methanamine so formed in the process of the invention is hydrogenated to form sertraline which may be further resolved by the use of, e.g., mandelic acid and finally crystallized as (1S- cis)-4-(3,4-dichlorophenyl)-l ,2,3,4-tetrahydro-N-methyl-l -naphthalenamine hydrochloride or some other pharmaceutically suitable salt.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising (lS-cis)-4-(3,4-dichlorophenyl)-l ,2,3,4-tetrahydro-N- methyl-l -naphthalenamine or its hydrochloride or some other pharmaceutically suitable salt prepared by the process of the invention.
  • the solvent used in the imination step is dimethylformamide or methylformamide, most preferably, the solvent is dimethylformamide.
  • the imination of 4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)-naphthalenone with monomethylamine may be performed in the presence of acid catalyst, which can be any suitable organic or inorganic acid, e.g., formic acid, acetic acid, sulfonic acid, or hydrochloric acid. In a preferred embodiment of the invention, formic acid or acetic acid is used as the acid catalyst.
  • the solubility of the product in the solvent of the invention is low, so that the product is slowly crystallizing out of the reaction mixture and it can be isolated easily by, e.g., filtration.
  • the process has also considerable purification capacity.
  • the reaction can be performed under atmospheric pressure and is typically carried out at a temperature in the range of from about 0 °C to about 50 °C, preferably at ambient temperature, i.e., from about 15 °C to about 25 °C.
  • the imination may also be carried out under a slight positive pressure of an inert atmosphere, such as nitrogen gas or argon gas.
  • the 4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)-naphthalenone is added to the solvent in an amount of about 300 g to about 400 g per liter of solvent, preferably about 320 g to about 350 g per liter of solvent.
  • the methylamine is added in an amount of about 4 mole to about 6 mole per mole of 4-(3,4-dichlorophenyl)- 3,4-dihydro-l-(2H)-naphthalenone, preferably about 4.8 mole to about 5.2 mole per mole of 4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)-naphthalenone.
  • the acid catalyst is typically added to the mixture in an amount of about 0.1 mole to about 2.0 mole per mole of 4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)- naphthalenone, preferably about 0.4 mole to about 0.6 mole per mole of 4-(3,4- dichlorophenyl)-3,4-dihydro-l-(2H)-naphthalenone.
  • the present method is not constrained to any particular order of addition, and the reaction may be conveniently performed by charging all of the components into a suitable-size vessel at 0 °C and then allowing the reaction mixture to rise to ambient temperature. The reaction mixture is then stirred at ambient temperature for a time of about 10 to about 30 hours, preferably about 20 to about 24 hours. If desired, the progress of the reaction may be monitored by any suitable technique, including chromatography, especially high-pressure liquid chromatography (HPLC) or thin- layer chromatography (TLC).
  • HPLC high-pressure liquid chromatography
  • TLC thin- layer chromatography
  • the resulting imine compound, N-[4-(3,4-dichlorophenyl)-3,4-dihydro- l(2H)-naphthalenylidene]methanamine is insoluble in the reaction solvent and exists as a solid precipitate in the reaction mixture at the completion of the reaction.
  • the resulting imine compound, N-[4-(3,4-dichlorophenyl)-3,4-dihydro-l(2H)- naphthalenylidene]methanamine may then be isolated from the reaction mixture by any suitable solid-liquid separation technique, such as filtration, centrifugation, or decantation.
  • the resulting imine compound, N-[4-(3,4-dichlorophenyl)-3,4-dihydro- l(2H)-naphthalenylidene]methanamine may be further hydrogenated to form cis- ( 1 S)( 1 R)- 4-(3 ,4-dichlorophenyl)- 1 ,2,3 ,4-tetrahydro-N-methyl- 1 -naphthalenamine which may then be optically resolved with, e.g., mandelic acid and finally crystallized to afford (lS-cis)-4-(3,4-dichlorophenyl)-l,2,3,4-tetrahydro-N-methyl-l- naphthalenamine hydrochloride or some other pharmaceutically suitable salt.
  • compositions comprising (lS-cis)-4-(3,4-dichlorophenyl)- 1 ,2,3 ,4-tetrahydro-N-methyl- 1 -naphthalenamine or its pharmaceutically suitable salt prepared by the method of the invention can be prepared by methods well-known in the art.
  • N-[4-(3,4-dichlorophenyl)-3,4-dihydro-l(2H)-naphthalenylidene]- methanamine 50 g is hydrogenated over palladium on charcoal to yield cis- (lS)(lR)- 4-(3,4-dichlorophenyl)-l,2,3,4-tetrahydro-N-methyl-l-naphthalenamine.
  • the rasemic compound is resolved by mandelic acid and finally crystallized as sertraline hydrochloride.
  • the total yield from 4-(3,4-dichlorophenyl)-3,4-dihydro-l- (2H)-naphtalenone is 67 % (of the theoretical (+)-enantiomer).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A pharmaceutical intermediate, N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine, which can be used in the production of sertraline hydrochloride, is conveniently prepared by reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-1-(2H)-naphthalenone with monomethylamine in a solvent which is an amide solvent with a structure of general formula (IV), wherein R1, R3 are indepen dently hydrogen or C1-6 alkyl, which can be substituted, and R2 is hydrogen.

Description

PROCESS FOR PREPARING SERTRALINE INTERMEDIATES
The present invention relates to a novel method for the production of sertraline. The present invention also relates to a novel process for the preparation of a pharmaceutical intermediate, N-[4-(3,4-dichlorophenyl)-3,4-dihydro-l(2H)- naphtalenylidene]methanamine.
BACKGROUND OF THE INVENTION
N- [4-(3 ,4-dichlorophenyl)-3 ,4-dihydro- 1 (2H)-naphtalenylidene]- methanamine of formula I
Figure imgf000002_0001
is a well known pharmaceutical intermediate which can be used e.g. in the preparation of sertraline, (lS-cis)-4-(3,4-dichlorophenyl)-l,2,3,4-tetrahydro-N- methyl-1-naphthalenamine, which has a structure of formula II
Figure imgf000002_0002
Sertraline is marketed in the form of its hydrochloride for the treatment of depression, obsessive-compulsive disorder and panic disorder.
The synthesis of sertraline is described in U.S. Patent no. 4,536,518. The process described includes a condensation reaction of 4-(3,4-dichlorophenyl)-3,4- dihydro- 1 (2H)-naphtalenone of formula III
Figure imgf000003_0001
with monomethylamine, which is catalyzed by titanium tetrachloride yielding N-[4- (3,4-dichlorophenyl)-3,4-dihydro-l(2H)-naphtalenylidene]methanamine. The reaction is an equilibrium reaction, where the equilibrium has to be shifted. This can be done e.g. by using titanium tetrachloride to remove water from the reaction mixture. Titanium tetrachloride, however, is extremely reactive with water and side products formed are hazardous, and therefore other dehydrating agents have been considered.
Another route to N-4-[3,4-dichlorophenyl)-3,4-dihydro-l(2H)- naphtalenylidene]methanamine is described in U.S. Patent No. 4,855,500, wherein the dehydration characteristics of appropriate mesh molecular sieves are employed to remove water from the reaction mixture to promote the condensation reaction between 4-(3,4-dichlorophenyl)-3,4-dihydro-l(2H)-naphtalenone and monomethylamine. Molecular sieves are expensive and they must typically be regenerated if they are to be reused.
In a process described in EP 1 059 287 (+) enantiomer of sertraline is prepared by either of the processes described above using (+) enantiomer of 4-(3,4- dichlorophenyl)-3,4-dihydro-l(2H)-naphtalenone as a starting material, so that no resolution of the final product is needed. Still another route to to N-4-[3,4-dichlorophenyl)-3,4-dihydro-l(2H)- naphtalenylidene]methanamine is described in the patent application WO 99/36394. In the process described the condensation reaction of 4-(3,4-dichlorophenyl)-3,4- dihydro-l(2H)-naphtalenone with monomethylamine is performed in an alcohol solvent. The solubility of the reaction product to the solvent is such that the equilibrium is favorably enhanced towards the product. No catalysts or dehydrating agents are needed. However, monomethylamine is easily vaporized in reaction temperatures (about 50 deg C or above) and therefore a suitable pressure rated vessel is needed and the reaction is carried out under pressure.
Sertraline hydrochloride is produced by further hydrogenating the N-4-[3,4- dichlorophenyl)-3,4-dihydro-l(2H)-naphtalenylidene]methanamine resulted from processes above and resolving the racemic mixture and finally crystallizing sertraline hydrochloride.
Now we have surprisingly found, that if the solvent for the imination process is selected from the solvents of the invention, the reaction can be performed in atmospheric pressure and ambient temperature. Also the amount of the solvent needed is low, impurities are not formed and the yield is good. Water removal agents like titanium tetrachloride or molecular sieves are not needed.
Another aspect of this invention relates to the process wherein the imine product formed in the process of the invention is hydrogenated to form sertraline which is further resolved by e.g. mandelic acid and finally crystallized as (lS-cis)-4- (3,4-dichlorophenyl)-l,2,3,4-tetrahydro-N-methyl-l-naphthalenamine hydrochloride or some other pharmaceutically suitable salt.
Still another aspect of the invention is a pharmaceutical composition comprising ( 1 S-cis)-4-(3,4-dichlorophenyl)- 1 ,2,3 ,4-tetrahydro-N-methyl- 1 - naphthalenamine or its hydrochloride or some other pharmaceutically suitable salt prepared by the process of the invention. DESCRIPTION OF THE INVENTION
In a first embodiment, the present invention provides a process for producing N-[4-(3,4-dichlorophenyl)-3,4-dihydro-l(2H)-naphthalenylidene]methanamine, by reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)-naphthalenone with monomethylamine in a solvent selected from the a group consisting of amide solvents of general formula IV:
R2
IV
N- "R1
R3
wherein Rl and R3 are independently hydrogen or C1-6 alkyl, which can be substituted, and R2 is hydrogen.
In another embodiment, the present invention provides a process wherein the N-[4-(3,4-dichlorophenyl)-3,4-dihydro- 1 (2H)-naphthalenylidene]methanamine so formed in the process of the invention is hydrogenated to form sertraline which may be further resolved by the use of, e.g., mandelic acid and finally crystallized as (1S- cis)-4-(3,4-dichlorophenyl)-l ,2,3,4-tetrahydro-N-methyl-l -naphthalenamine hydrochloride or some other pharmaceutically suitable salt.
In still another embodiment, the present invention provides a pharmaceutical composition comprising (lS-cis)-4-(3,4-dichlorophenyl)-l ,2,3,4-tetrahydro-N- methyl-l -naphthalenamine or its hydrochloride or some other pharmaceutically suitable salt prepared by the process of the invention.
In a preferred embodiment of the present invention the solvent used in the imination step is dimethylformamide or methylformamide, most preferably, the solvent is dimethylformamide. The imination of 4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)-naphthalenone with monomethylamine may be performed in the presence of acid catalyst, which can be any suitable organic or inorganic acid, e.g., formic acid, acetic acid, sulfonic acid, or hydrochloric acid. In a preferred embodiment of the invention, formic acid or acetic acid is used as the acid catalyst.
The solubility of the product in the solvent of the invention is low, so that the product is slowly crystallizing out of the reaction mixture and it can be isolated easily by, e.g., filtration. The process has also considerable purification capacity. The reaction can be performed under atmospheric pressure and is typically carried out at a temperature in the range of from about 0 °C to about 50 °C, preferably at ambient temperature, i.e., from about 15 °C to about 25 °C. Of course, the imination may also be carried out under a slight positive pressure of an inert atmosphere, such as nitrogen gas or argon gas.
Suitably, the 4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)-naphthalenone is added to the solvent in an amount of about 300 g to about 400 g per liter of solvent, preferably about 320 g to about 350 g per liter of solvent. The methylamine is added in an amount of about 4 mole to about 6 mole per mole of 4-(3,4-dichlorophenyl)- 3,4-dihydro-l-(2H)-naphthalenone, preferably about 4.8 mole to about 5.2 mole per mole of 4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)-naphthalenone. When used, the acid catalyst is typically added to the mixture in an amount of about 0.1 mole to about 2.0 mole per mole of 4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)- naphthalenone, preferably about 0.4 mole to about 0.6 mole per mole of 4-(3,4- dichlorophenyl)-3,4-dihydro-l-(2H)-naphthalenone.
The present method is not constrained to any particular order of addition, and the reaction may be conveniently performed by charging all of the components into a suitable-size vessel at 0 °C and then allowing the reaction mixture to rise to ambient temperature. The reaction mixture is then stirred at ambient temperature for a time of about 10 to about 30 hours, preferably about 20 to about 24 hours. If desired, the progress of the reaction may be monitored by any suitable technique, including chromatography, especially high-pressure liquid chromatography (HPLC) or thin- layer chromatography (TLC). The resulting imine compound, N-[4-(3,4-dichlorophenyl)-3,4-dihydro- l(2H)-naphthalenylidene]methanamine is insoluble in the reaction solvent and exists as a solid precipitate in the reaction mixture at the completion of the reaction. The resulting imine compound, N-[4-(3,4-dichlorophenyl)-3,4-dihydro-l(2H)- naphthalenylidene]methanamine may then be isolated from the reaction mixture by any suitable solid-liquid separation technique, such as filtration, centrifugation, or decantation.
The resulting imine compound, N-[4-(3,4-dichlorophenyl)-3,4-dihydro- l(2H)-naphthalenylidene]methanamine may be further hydrogenated to form cis- ( 1 S)( 1 R)- 4-(3 ,4-dichlorophenyl)- 1 ,2,3 ,4-tetrahydro-N-methyl- 1 -naphthalenamine which may then be optically resolved with, e.g., mandelic acid and finally crystallized to afford (lS-cis)-4-(3,4-dichlorophenyl)-l,2,3,4-tetrahydro-N-methyl-l- naphthalenamine hydrochloride or some other pharmaceutically suitable salt.
Pharmaceutical compositions comprising (lS-cis)-4-(3,4-dichlorophenyl)- 1 ,2,3 ,4-tetrahydro-N-methyl- 1 -naphthalenamine or its pharmaceutically suitable salt prepared by the method of the invention can be prepared by methods well-known in the art.
The following examples are used to illustrate but by no means to limit the scope of the invention, which is defined in the claims.
EXAMPLE 1.
Preparation of N-[4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)- naphthalenylidenej-methanamine
4-(3,4-Dichloroρhenyl)-3,4-dihydro-l-(2H)-naphtalenone (100 g), N,N- dimethylformamide (300 ml) and formic acid (6.5 ml) are charged. Methylamine (56.0 g) is added at about 0 °C. The mixture is stirred for 20 hours at room temperature. The mixture is cooled to 10 °C and stirred for 1 hour. The crystalline compound is filtered and washed with methanol. The yield is 97.7 g (93.5 %) as dried. The same process was performed using N-methylformamide as a solvent in the imination step. Yield was 90.1 %.
EXAMPLE 2.
Preparation of (lS-cis)-4-(3 ,4-dichlorophenyl)- 1,2,3,4-tetrahydro-N-methyl- 1 -naphthalenamine hydrochloride (sertraline hydrochloride)
N-[4-(3,4-dichlorophenyl)-3,4-dihydro-l(2H)-naphthalenylidene]- methanamine (50 g) is hydrogenated over palladium on charcoal to yield cis- (lS)(lR)- 4-(3,4-dichlorophenyl)-l,2,3,4-tetrahydro-N-methyl-l-naphthalenamine. The rasemic compound is resolved by mandelic acid and finally crystallized as sertraline hydrochloride. The total yield from 4-(3,4-dichlorophenyl)-3,4-dihydro-l- (2H)-naphtalenone is 67 % (of the theoretical (+)-enantiomer).

Claims

1. A process for preparing N-[4-(3,4-dichlorophenyl)-3,4-dihydro-l(2H)- naphthalenylidene]mefhanamine of formula I:
Figure imgf000009_0001
said process comprising:
(1) reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)-naphthalenone of formula III:
Figure imgf000009_0002
with monomethylamine in a solvent which is selected from the group consisting of amide solvents with a structure of general formula IV: R2-
IV
N— R1
/
R3
wherein Rl and R3 are independently hydrogen or C, 6 alkyl, which can be substituted and R2 is hydrogen.
2. A process according to claim 1 wherein the solvent is dimethylformamide or methylformamide.
3. A process according to claim 2 wherein the solvent used is dimethylformamide.
4. A process according to any of claims 1 to 3 wherein the reaction is performed in the presence of an acid catalyst.
5. A process according to any of claim 4 wherein the acid catalyst is formic acid or acetic acid.
6. A process according to any of claims 1 to 5 wherein the reaction is performed in the temperature range from about 0 deg C to about 50 deg C.
7. A process for producing (lS-cis)-4-(3 ,4-dichlorophenyl)- 1,2,3, 4- tetrahydro-N-methyl- 1 -naphthalenamine or pharmaceutically acceptable salt thereof, which has the structure of formula II:
Figure imgf000010_0001
said process comprising:
(1) reacting 4-(3,4-dichlorophenyl)-3,4-dihydro-l-(2H)-naphthalenone of formula HI:
Figure imgf000011_0001
with monomethylamine in a solvent which is selected from the group consisting of amide solvents with a structure of general formula IV:
∞- IV
N— R1
/
R3
wherein Rl and R3 are independently hydrogen or C1 6 alkyl, which can be substituted and R2 is hydrogen to obtain N-[4-(3,4-dichlorophenyl)-3,4-dihydro- 1 (2H)-naphthalenylidene]-methanamine of formula I:
Figure imgf000011_0002
(2) hydrogenating said N-[4-(3,4-dichlorophenyl)-3,4-dihydro-l(2H)- naphthalenylidene]methanamine of formula I to obtain a mixture of racemic cis sertraline and racemic trans sertraline, and
(3) resolving said mixture of racemic cis sertraline and racemic trans sertraline to obtain said (lS-cis)-4-(3,4-dichlorophenyl)-l,2,3,4-tetrahydro-N- methyl-1 -naphthalenamine or pharmaceutically acceptable salt thereof.
8. A process according to claim 6 wherein the mixture of racemic cis sertraline and racemic trans sertraline is resolved by mandelic acid.
9. A process of claim 6 or 7 wherein said pharmaceutically acceptable salt is hydrochloride.
10. A pharmaceutical composition comprising (lS-cis)-4-(3,4- dichlorophenyl)- 1 ,2,3,4-tetrahydro-N-methyl- 1 -naphthalenamine hydrochloride prepared by the process of claim 6 or 7.
PCT/FI2002/000466 2001-05-31 2002-05-30 Process for preparing sertraline intermediates WO2002096860A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002448300A CA2448300A1 (en) 2001-05-31 2002-05-30 Process for preparing sertraline intermediates
EP02727626A EP1397342A1 (en) 2001-05-31 2002-05-30 Process for preparing sertraline intermediates

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29426601P 2001-05-31 2001-05-31
FI20011146A FI20011146A0 (en) 2001-05-31 2001-05-31 New manufacturing method
FI20011146 2001-05-31
US60/294,266 2001-05-31

Publications (1)

Publication Number Publication Date
WO2002096860A1 true WO2002096860A1 (en) 2002-12-05

Family

ID=26161179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2002/000466 WO2002096860A1 (en) 2001-05-31 2002-05-30 Process for preparing sertraline intermediates

Country Status (3)

Country Link
EP (1) EP1397342A1 (en)
CA (1) CA2448300A1 (en)
WO (1) WO2002096860A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124920A1 (en) * 2006-04-28 2007-11-08 Sandoz Ag Process for the preparation of [4(s,r)-(3,4-dichlorophenyl)-3,4-dihydro-1(2h)-naphthalen-1-ylidene]methylamine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027050A1 (en) * 1996-12-18 1998-06-25 Richter Gedeon Vegyészeti Gyár Rt. Process for preparing a naphtalenamine derivative
WO1999036394A1 (en) * 1998-01-16 1999-07-22 Pfizer Products Inc. Novel process for preparing a ketimine
EP1059287A1 (en) * 1999-06-09 2000-12-13 Pfizer Products Inc. Process for preparing sertraline from chiral tetralone
WO2001016089A1 (en) * 1999-09-01 2001-03-08 Sharad Kumar Vyas A process for the preparation of cis-(1s,4s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine hydrochloride
WO2001036378A1 (en) * 1999-11-16 2001-05-25 Ciba Specialty Chemicals Holding Inc. Process for the preparation of ketimines
WO2001036377A1 (en) * 1999-11-16 2001-05-25 Ciba Specialty Chemicals Holding Inc. Process for the preparation of ketimines
US20010041815A1 (en) * 1999-12-21 2001-11-15 Judith Aronhime Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027050A1 (en) * 1996-12-18 1998-06-25 Richter Gedeon Vegyészeti Gyár Rt. Process for preparing a naphtalenamine derivative
WO1999036394A1 (en) * 1998-01-16 1999-07-22 Pfizer Products Inc. Novel process for preparing a ketimine
EP1059287A1 (en) * 1999-06-09 2000-12-13 Pfizer Products Inc. Process for preparing sertraline from chiral tetralone
WO2001016089A1 (en) * 1999-09-01 2001-03-08 Sharad Kumar Vyas A process for the preparation of cis-(1s,4s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine hydrochloride
WO2001036378A1 (en) * 1999-11-16 2001-05-25 Ciba Specialty Chemicals Holding Inc. Process for the preparation of ketimines
WO2001036377A1 (en) * 1999-11-16 2001-05-25 Ciba Specialty Chemicals Holding Inc. Process for the preparation of ketimines
US20010041815A1 (en) * 1999-12-21 2001-11-15 Judith Aronhime Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHAEL P. DENINNO ET AL: "The preparation and intra-and intermocular addition reactions of acylic n-acylimines: Application to the synthesis of (+-) sertraline", J.ORG.CHEM, vol. 66, 2001, pages 6988 - 6993, XP002902612 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124920A1 (en) * 2006-04-28 2007-11-08 Sandoz Ag Process for the preparation of [4(s,r)-(3,4-dichlorophenyl)-3,4-dihydro-1(2h)-naphthalen-1-ylidene]methylamine

Also Published As

Publication number Publication date
CA2448300A1 (en) 2002-12-05
EP1397342A1 (en) 2004-03-17

Similar Documents

Publication Publication Date Title
US6552227B2 (en) Process for preparing (+)-cis-sertraline
US6593496B1 (en) Process for preparing sertraline from chiral tetralone
AU2001243634A1 (en) Novel process for preparing (+)-cis-sertraline
TW505624B (en) Novel process for preparing a ketimine
US6635773B2 (en) Process for preparing citalopram
WO2001016089A1 (en) A process for the preparation of cis-(1s,4s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine hydrochloride
WO2002096860A1 (en) Process for preparing sertraline intermediates
US20030013768A1 (en) Process for the production of sertraline and intermediates useful therefor
WO2006027658A2 (en) Process for the preparation of sertraline hydrochloride form ii
US7728147B2 (en) Detomidine hydrochloride crystallization method
WO2005012224A1 (en) Sertraline hydrochloride form ii and methods for the preparation thereof
EP1401800A1 (en) A novel process for the preparation of (is-cis) -4-(3, 4-dichlorophenyl) -1, 2, 3, 4 - tetrahydro-n-methyl-1-naphthalenamine
WO2006134219A2 (en) Atipamezhole hydrochloride crystallization method
WO2005007611A2 (en) Process for the preparation of an imine intermediate
AU2006201492A1 (en) Novel process for preparing (+)-cis-sertraline
WO2007071421A1 (en) An improved process for the preparation of sertraline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2448300

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002727626

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002727626

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002727626

Country of ref document: EP